Genmab (GMAB) AI Stock Analysis

• Market Cap: $13.52B
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): 12.2
• Beta (1Y): 0.56
• Revenue Growth: 25.11%
• EPS Growth: 46.46%
• Country: US
• Employees: 2,638
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 0.30
• Shares Outstanding: 641,542,540
• 10 Day Avg. Volume: 946,916
• 30 Day Avg. Volume: 1,318,961
• PEG Ratio: -0.93
• Price to Book (P/B): 16.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $34.50
• Price Target Upside: 58.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 72 Outperform
• Price Target: $23.50 ▲(7.90%Upside)

Genmab's strong financial performance is the primary driver of its stock score, reflecting solid profitability and financial stability. Valuation is favorable with a low P/E ratio, but technical analysis indicates mixed momentum signals. The absence of a dividend yield and lack of recent earnings call insights are secondary factors.

Positive Factors

Clinical Trials

Genmab's commitment to initiate a Phase III study for Rina-S in endometrial cancer shows a strong resolve to advance treatment options.

Efficacy Data

Rina-S demonstrates a promising overall response rate in endometrial cancer, surpassing standard-of-care treatments and other non-HER2 ADCs.

Pipeline Development

Genmab and partners disclose data from multiple programs, indicating a robust and diversified pipeline.

Negative Factors

Competitive Landscape

Rina-S faces growing competition, challenging its positioning despite strong clinical profiles.

Safety Concerns

Potential concerns around myelosuppression are addressed as part of Rina-S's development strategy.

Genmab Business Overview & Revenue Model

Company Description

Genmab A/S is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company operates primarily in the healthcare and biotechnology sectors, leveraging its proprietary technology platforms to develop a robust pipeline of innovative antibody therapeutics. Genmab's core products include approved medicines like DARZALEX, Kesimpta, and TEPEZZA, which are developed in collaboration with leading pharmaceutical companies.

How the Company Makes Money

Genmab generates revenue through a combination of royalties, collaboration agreements, and milestone payments. A significant portion of its revenue comes from royalties on sales of its marketed products, such as DARZALEX, which is commercialized by Janssen Biotech, a subsidiary of Johnson & Johnson. The company also enters into strategic partnerships and licensing agreements with major pharmaceutical companies to co-develop and commercialize its antibody products, which provides upfront payments, development milestones, and sales-based royalties. Additionally, Genmab invests in its own proprietary product pipeline with the potential for future commercialization, thus creating multiple avenues for revenue generation.

Genmab Financial Statement Overview

Summary

Genmab demonstrates robust financial health with strong profitability, a solid balance sheet, and effective cash flow management. Despite a slight recent revenue decline, the company maintains a strong market position with efficient operations and low leverage, providing resilience against market volatility.

Income Statement

Genmab exhibits strong profitability with a consistent gross profit margin exceeding 95% across the years. The net profit margin for TTM is a robust 37.1%, highlighting effective cost management. Revenue growth is evident, although there was a decline in the most recent period compared to the previous year, indicating potential market fluctuations or competitive pressures.

Balance Sheet

The balance sheet reflects strong financial stability with a low debt-to-equity ratio of 0.027 in TTM, indicating low financial leverage. The equity ratio is high, around 80.4%, showcasing a solid equity base. Return on equity is impressive at 12.7%, reflecting efficient use of equity capital.

Cash Flow

Cash flow statements reveal a strong cash generation capability, with a high operating cash flow to net income ratio of 0.97 and a free cash flow to net income ratio of 0.95 in TTM. However, free cash flow growth has seen some fluctuations, indicating potential investment cycles or operational changes.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.32B	21.53B	16.47B	14.60B	8.48B	10.11B
Gross Profit	21.23B	20.54B	16.25B	14.60B	8.48B	10.11B
EBITDA	6.62B	9.70B	5.56B	7.35B	3.15B	6.54B
Net Income	6.71B	7.84B	4.35B	5.45B	2.96B	4.76B
Balance Sheet
Total Assets	6.59B	45.81B	35.29B	30.28B	24.63B	21.14B
Cash, Cash Equivalents and Short-Term Investments	3.23B	21.10B	28.14B	22.32B	19.34B	16.08B
Total Debt	143.00M	1.03B	770.00M	597.00M	425.00M	319.00M
Total Liabilities	1.29B	9.11B	3.68B	2.84B	2.43B	2.02B
Stockholders Equity	5.30B	36.70B	31.61B	27.44B	22.20B	19.12B
Cash Flow
Free Cash Flow	6.35B	7.58B	7.00B	3.60B	1.98B	6.13B
Operating Cash Flow	6.54B	7.77B	7.38B	3.91B	2.23B	6.43B
Investing Cash Flow	-8.51B	-9.91B	-1.28B	-2.76B	-961.00M	-2.35B
Financing Cash Flow	-3.34B	-3.92B	-606.00M	-789.00M	-420.00M	71.00M

Genmab Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 21.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMAB, the sentiment is Neutral. The current price of 21.78 is below the 20-day moving average (MA) of 21.99, above the 50-day MA of 21.65, and above the 200-day MA of 21.13, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 48.59 is Neutral, neither overbought nor oversold. The STOCH value of 17.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GMAB.

Genmab Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	78 Outperform	$11.09B	21.47	9.64%	―	17.99%	152.10%
UTHR	77 Outperform	$13.31B	11.49	19.30%	―	17.62%	19.89%
INCY	75 Outperform	$14.62B	17.03	24.30%	―	18.87%	1088.27%
EXEL	73 Outperform	$9.75B	17.37	29.00%	―	10.73%	81.66%
GMAB	72 Outperform	$13.52B	12.16	22.69%	―	25.11%	46.46%
Sector *	47 Neutral	C$191.05M	-3.08	-23.59%	2.88%	21.41%	-1.52%
ASND	43 Neutral	$10.53B	―	357.68%	―	10.69%	34.71%